Date:11/11/2010

n these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Transcept makes, including the following: new information arising out of clinical trial results and FDA interpretation of our study results; the competitive landscape for Intermezzo®; dependence on third parties to manufacture supply of product candidates for current and planned studies and conduct such studies; the outcomes from planned Phase 1 studies of TO-2061; the FDA's view of the sufficiency of the anticipated content of the planned Intermezzo® NDA resubmission to support FDA review and approval; unforeseen expenses or delays related to our plans to support FDA approval of Intermezzo®, the development of TO-2061, and the business of Transcept generally; and the ability of Transcept to obtain additional funding, if needed, to support its business activities.  These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law.FINANCIAL TABLES FOLLOWTranscept Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)Three Months Ended September 30, Nine Months Ended September 30, 2010200920102009Revenue:License fee revenue

$  3,125$  2,083$  9,375$
2,083Operating expense:Research and development

2,8852,1367,6526,608General and administrati
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Transcept Pharmaceuticals to Report Third Quarter 2010 Results and Host Conference Call on November 11, 2010
2. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
3. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
4. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
5. Transcept Pharmaceuticals to Present at BIO Investor Forum
6. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
7. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
8. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
9. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
10. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
11. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17